Authors' objectives: Sofosbuvir-velpatasvir (Epclusa) is a "next-generation" once-daily direct-acting antiretroviral (DAA) combination oral regimen for the treatment of all 6 major hepatitis C virus (HCV) genotypes. The fixed-dose combination pill contains 400 mg of sofosbuvir and 100 mg of velpatasvir. Rationale: Sofosbuvir-velpatasvir is intended to treat any genotype and subtype of HCV using an existing drug with accepted efficacy, plus a new drug that is intended to improve efficacy by targeting HCV in a different way. Relevant Questions: Does sofosbuvir-velpatasvir result in high rates of sustained virologic response (SVR) and low rates of treatment failure (i.e., virologic relapse)? How does sofosbuvir-velpatasvir compare with other treatments for HCV for increasing SVR rates, reducing treatment failure (i.e., virologic relapse) rates, or improving patient-oriented outcomes (e.g., quality of life)? What harms and complications are associated with sofosbuvir-velpatasvir? Have definitive patient selection criteria been established for sofosbuvir-velpatasvir for treatment of chronic HCV infection?

Project Status: Completed

Year Published: 2016

URL for published report: The report may be purchased from:http://www.hayesinc.com/hayes/crd/?crd=52386

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: United States

Organisation Name: HAYES, Inc.

Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218

Contact Name: saleinfo@hayesinc.com

Contact Email: saleinfo@hayesinc.com

Copyright: Winifred S. Hayes, Inc